Sameek Roychowdhury, MD, PhD, is a member of the Translational Therapeutics Program at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), where he is working to identify putative predictive genomic biomarkers for targeted therapies and to understand resistance mechanisms for those therapies. His research involves translating next-generation DNA-sequencing strategies for genomics-driven clinical trials. In particular, he is working with advanced-cancer patients considering clinical trials to identify driving mutations that match novel molecularly targeted therapies in development.
Dr. Roychowdhury has co-authored more than a dozen articles in well-respected publications, including Journal of the American Medical Association, Journal of the National Cancer Institute, Human Mutation and Journal of Clinical Oncology.
The Ohio State Comprehensive Cancer Center is also a founding member of the Oncology Research Information Exchange Network (ORIEN), a unique research partnership among North America’s top cancer centers that recognize collaboration and access to data are the keys to cancer discovery. Through ORIEN, founders OSUCCC-James and the Moffitt Cancer Center in Tampa leverage multiple data sources and match patients to targeted treatments.